表紙
市場調查報告書

關注市場分析:子宮內膜異位症

Market Spotlight: Endometriosis

出版商 Datamonitor Healthcare 商品編碼 573556
出版日期 內容資訊 英文 36 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:子宮內膜異位症 Market Spotlight: Endometriosis
出版日期: 2019年10月18日內容資訊: 英文 36 Pages
簡介

全球15-49歲的女性人口的子宮內膜異位症的患病人數,預計從2016年的1億8690萬人,到2025年增加到1億9660萬人。

本報告提供全球子宮內膜異位症的市場調查,疾病的背景、概要,患病人數的10年預測,開發平台藥物及已上市藥物概要,臨床試驗狀況,授權、資產收購等的主要交易趨勢,專利資訊,主要藥物的收益預測等彙整資料。

要點

疾病的背景

治療藥

流行病學

開發平台藥物

已上市藥物

  • 核准:各國

今後的主要活動

授權、資產收購等的交易

  • 武田藥品工業

本源專利

商機

臨床試驗環境

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0178894

This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 188.7 million prevalent cases of endometriosis in women aged 15-49 years worldwide, and forecasts that number to increase to 199.1 million prevalent cases by

2026. Endometriosis affects an estimated one in 10 women in the reproductive age group of 15-49 years. The approved drugs in the endometriosis space target the gonadotropin-releasing hormone receptor, progesterone receptor, follicle-stimulating hormone, and androgen receptors. The majority of marketed drugs are administered via the subcutaneous route, while oral and intramuscular formulations are also available.

Half of the industry-sponsored drugs in active clinical development for endometriosis are in Phase II, with two drugs in Phase III. Therapies in mid-to-late-stage development for endometriosis focus on targets such as the gonadotropin-releasing hormone receptor, progesterone receptor, luteinizing hormone receptor, androgen receptors, and follicle-stimulating hormone. The majority of pipeline drugs in mid-to-late-stage development for endometriosis are administered via the oral route, with only one product being tested as a topical formulation.

High-impact upcoming events in the endometriosis space comprise topline Phase III results for two trials of relugolix. The overall likelihood of approval of a Phase I gynecology asset is 14.8%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 10.7 years from Phase I to approval, compared to 12.4 years in the overall obstetrics/gynecology space.

There have been 13 licensing and asset acquisition deals involving endometriosis drugs during 2014-19. The largest deal was in 2017, when AstraZeneca obtained commercialization rights to Zoladex in the US and Canada from TerSera Therapeutics for $320m.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for endometriosis have been in the early and mid-phases of development, with 74% of trials in Phase I-II, and only 26% in Phase III-IV.

The US has a substantial lead in the number of endometriosis clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the endometriosis space is dominated by completed trials. Bayer has the highest number of completed clinical trials for endometriosis, with 38 trials.

Bayer leads industry sponsors with the highest overall number of clinical trials for endometriosis, followed by Takeda.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • GnRH analogs
  • Progestins
  • Combined oral contraceptives
  • Non-steroidal anti-inflammatory drugs
  • Danocrine
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Proellex (Oral) for Endometriosis (June 25, 2019)
  • Linzagolix for Endometriosis (June 18, 2018)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Bayer, Hope Medicine Strike Hair Loss Antibody License
  • Daewon Licenses Tium's Novel Endometriosis Therapeutic

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of endometriosis, 2017-26
  • Figure 2: Overview of pipeline drugs for endometriosis in the US
  • Figure 3: Pipeline drugs for endometriosis, by company
  • Figure 4: Pipeline drugs for endometriosis, by drug type
  • Figure 5: Pipeline drugs for endometriosis, by classification
  • Figure 6: Linzagolix for Endometriosis (June 18, 2018): Phase IIb - EDELWEISS
  • Figure 7: Key upcoming events in endometriosis
  • Figure 8: Probability of success in the endometriosis pipeline
  • Figure 9: Licensing and asset acquisition deals in endometriosis, 2014-19
  • Figure 10: Parent patents in endometriosis
  • Figure 11: Clinical trials in endometriosis
  • Figure 12: Top 10 drugs for clinical trials in endometriosis
  • Figure 13: Top 10 companies for clinical trials in endometriosis
  • Figure 14: Trial locations in endometriosis
  • Figure 15: Endometriosis trials status
  • Figure 16: Endometriosis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of endometriosis, 2017-26
  • Table 2: Marketed drugs for endometriosis
  • Table 3: Pipeline drugs for endometriosis in the US
  • Table 4: Proellex (Oral) for Endometriosis (June 25, 2019)
  • Table 5: Linzagolix for Endometriosis (June 18, 2018)
  • Table 6: Historical global sales, by drug ($m), 2014-18
  • Table 7: Forecasted global sales, by drug ($m), 2019-23
Back to Top